Renin-angiotensin system blockade: Its contribution and controversy

Akira Miyajima, Takeo Kosaka, Eiji Kikuchi, Mototsugu Oya

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Angiotensin II is a key biological peptide in the renin-angiotensin system that regulates blood pressure and renal hemodynamics, and extensive experimental studies have shown that angiotensin II promotes diverse fibrotic changes and induces neovascularization in several inflammatory diseases. It is known that angiotensin II can be controlled using renin-angiotensin system blockade when angiotensin II is the main factor inducing a particular disease, and renin-angiotensin system blockade has assumed a central role in the treatment of inflammatory nephritis, cardiovascular disorders and retinopathy. In contrast, renin-angiotensin system blockade was found to have not only these effects but also other functions, such as inhibition of cancer growth, angiogenesis and metastasis. Numerous studies have sought to elucidate the mechanisms and support these antitumor effects. However, a recent meta-analysis showed that renin-angiotensin system blockade use might in fact increase the incidence of cancer, so renin-angiotensin system blockade use has become somewhat controversial. Although the renin-angiotensin system has most certainly made great contributions to experimental models and clinical practice, some issues still need to be resolved. The present review discusses the contribution and controversy surrounding the renin-angiotensin system up to the present time.

Original languageEnglish
Pages (from-to)721-730
Number of pages10
JournalInternational Journal of Urology
Volume22
Issue number8
DOIs
Publication statusPublished - 2015 Aug 1

Fingerprint

Renin-Angiotensin System
Angiotensin II
Nephritis
Meta-Analysis
Neoplasms
Theoretical Models
Hemodynamics
Neoplasm Metastasis
Blood Pressure
Kidney
Peptides
Incidence
Growth

Keywords

  • Angiogenesis
  • Angiotensin II
  • Carcinogenesis
  • Fibrosis
  • Inflammation

ASJC Scopus subject areas

  • Urology

Cite this

Renin-angiotensin system blockade : Its contribution and controversy. / Miyajima, Akira; Kosaka, Takeo; Kikuchi, Eiji; Oya, Mototsugu.

In: International Journal of Urology, Vol. 22, No. 8, 01.08.2015, p. 721-730.

Research output: Contribution to journalArticle

@article{f3d40ad5f9e34096aaec9631c1040954,
title = "Renin-angiotensin system blockade: Its contribution and controversy",
abstract = "Angiotensin II is a key biological peptide in the renin-angiotensin system that regulates blood pressure and renal hemodynamics, and extensive experimental studies have shown that angiotensin II promotes diverse fibrotic changes and induces neovascularization in several inflammatory diseases. It is known that angiotensin II can be controlled using renin-angiotensin system blockade when angiotensin II is the main factor inducing a particular disease, and renin-angiotensin system blockade has assumed a central role in the treatment of inflammatory nephritis, cardiovascular disorders and retinopathy. In contrast, renin-angiotensin system blockade was found to have not only these effects but also other functions, such as inhibition of cancer growth, angiogenesis and metastasis. Numerous studies have sought to elucidate the mechanisms and support these antitumor effects. However, a recent meta-analysis showed that renin-angiotensin system blockade use might in fact increase the incidence of cancer, so renin-angiotensin system blockade use has become somewhat controversial. Although the renin-angiotensin system has most certainly made great contributions to experimental models and clinical practice, some issues still need to be resolved. The present review discusses the contribution and controversy surrounding the renin-angiotensin system up to the present time.",
keywords = "Angiogenesis, Angiotensin II, Carcinogenesis, Fibrosis, Inflammation",
author = "Akira Miyajima and Takeo Kosaka and Eiji Kikuchi and Mototsugu Oya",
year = "2015",
month = "8",
day = "1",
doi = "10.1111/iju.12827",
language = "English",
volume = "22",
pages = "721--730",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Renin-angiotensin system blockade

T2 - Its contribution and controversy

AU - Miyajima, Akira

AU - Kosaka, Takeo

AU - Kikuchi, Eiji

AU - Oya, Mototsugu

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Angiotensin II is a key biological peptide in the renin-angiotensin system that regulates blood pressure and renal hemodynamics, and extensive experimental studies have shown that angiotensin II promotes diverse fibrotic changes and induces neovascularization in several inflammatory diseases. It is known that angiotensin II can be controlled using renin-angiotensin system blockade when angiotensin II is the main factor inducing a particular disease, and renin-angiotensin system blockade has assumed a central role in the treatment of inflammatory nephritis, cardiovascular disorders and retinopathy. In contrast, renin-angiotensin system blockade was found to have not only these effects but also other functions, such as inhibition of cancer growth, angiogenesis and metastasis. Numerous studies have sought to elucidate the mechanisms and support these antitumor effects. However, a recent meta-analysis showed that renin-angiotensin system blockade use might in fact increase the incidence of cancer, so renin-angiotensin system blockade use has become somewhat controversial. Although the renin-angiotensin system has most certainly made great contributions to experimental models and clinical practice, some issues still need to be resolved. The present review discusses the contribution and controversy surrounding the renin-angiotensin system up to the present time.

AB - Angiotensin II is a key biological peptide in the renin-angiotensin system that regulates blood pressure and renal hemodynamics, and extensive experimental studies have shown that angiotensin II promotes diverse fibrotic changes and induces neovascularization in several inflammatory diseases. It is known that angiotensin II can be controlled using renin-angiotensin system blockade when angiotensin II is the main factor inducing a particular disease, and renin-angiotensin system blockade has assumed a central role in the treatment of inflammatory nephritis, cardiovascular disorders and retinopathy. In contrast, renin-angiotensin system blockade was found to have not only these effects but also other functions, such as inhibition of cancer growth, angiogenesis and metastasis. Numerous studies have sought to elucidate the mechanisms and support these antitumor effects. However, a recent meta-analysis showed that renin-angiotensin system blockade use might in fact increase the incidence of cancer, so renin-angiotensin system blockade use has become somewhat controversial. Although the renin-angiotensin system has most certainly made great contributions to experimental models and clinical practice, some issues still need to be resolved. The present review discusses the contribution and controversy surrounding the renin-angiotensin system up to the present time.

KW - Angiogenesis

KW - Angiotensin II

KW - Carcinogenesis

KW - Fibrosis

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=84937938941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937938941&partnerID=8YFLogxK

U2 - 10.1111/iju.12827

DO - 10.1111/iju.12827

M3 - Article

C2 - 26032599

AN - SCOPUS:84937938941

VL - 22

SP - 721

EP - 730

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 8

ER -